. – Public Listing offers Access to CAD 52 Million from Share Subscription and Drawdown Agreement, Sufficient Funding to Complete Development and Launch Avisa BreathTest™ – Pivotal Trials Planned in Post-COVID-19 Long Haulers and Ventilator-Associated Pneumonia Avisa Diagnostics Inc. (Avisa) is pleased to announce that the Company has begun trading on the Canadian Securites ExchangeRead more about Avisa Diagnostics Begins Trading on the Canadian Securities Exchange[…]